{
    "eid": "2-s2.0-85058912177",
    "title": "Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV",
    "cover-date": "2018-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology and Allergy",
            "@code": "2723",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Immunology",
            "@code": "2403",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "bone mineral density",
        "HIV",
        "osteoporosis",
        "tenofovir",
        "zoledronic acid"
    ],
    "authors": [
        "Jennifer F. Hoy",
        "Robyn Richardson",
        "Peter R. Ebeling",
        "Jhon Rojas",
        "Nicholas Pocock",
        "Stephen J. Kerr",
        "Esteban Martinez",
        "Andrew Carr"
    ],
    "citedby-count": 17,
    "ref-count": 39,
    "ref-list": [
        "Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-Analytic review",
        "Continuous antiretroviral therapy decreases bone mineral density",
        "Immediate initiation of antiretroviral therapy for HIV infection accelerates bone loss relative to deferring therapy: findings from the START Bone Mineral Density Substudy, a randomized trial",
        "Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial",
        "Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202",
        "Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study",
        "Prospective study of bone mineral density changes in aging men with or at risk for HIV infection",
        "Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy",
        "Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006",
        "Increased risk of fragility fractures among HIV infected compared to uninfected male veterans",
        "Do people with HIV infection have a higher risk of fracture compared with those without HIV infection?",
        "Antiretrovirals, fractures, and osteonecrosis in a large international HIV cohort",
        "Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents",
        "Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system",
        "Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection",
        "Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV",
        "Annual zoledronate increases bone density in highly active antiretroviral therapy-Treated human immunodeficiency virus-infected men: A randomized controlled trial",
        "A doubleblinded, randomized controlled trial of zoledronate therapy for HIV-Associated osteopenia and osteoporosis",
        "Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks",
        "Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: A randomised, active-controlled, multicentre, open-label, phase 3, noninferiority study",
        "Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-Arm multicenter, open-label phase 3 study",
        "Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: A randomized, 96-week trial",
        "The role of DXA bone density scans in the diagnosis and treatment of osteoporosis",
        "The diagnosis of osteoporosis",
        "FRAX and the assessment of fracture probability in men and women from the UK",
        "Reversal of HIV-1-Associated osteoporosis with once-weekly alendronate",
        "Alendronate reduces bone resorption in HIV-Associated osteopenia/osteoporosis",
        "Intravenous zoledronic acid in postmenopausal women with low bone mineral density",
        "Lowdose zoledronate in osteopenic postmenopausal women: A randomized controlled trial",
        "Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis",
        "Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: Two-centre randomized pilot study (OsteoTDF study)",
        "Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: A randomized, placebo-controlled trial",
        "Treatment of calcium and vitamin D deficiency in HIV-positive men on tenofovir-containing antiretroviral therapy",
        "Vitamin D3 supplementation increases spine bone mineral density in adolescents and young adults with HIV infection being treated with tenofovir disoproxil fumarate: A randomized, placebocontrolled trial",
        "Efficacy and tolerability of initial antiretroviral therapy: A systematic review",
        "The ethics of switch/simplify in antiretroviral trials: noninferior or just inferior?"
    ],
    "affiliation": [
        {
            "affiliation-city": "Sydney",
            "@id": "60025702",
            "affilname": "St. Vincent's Hospital Sydney",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025702",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Melbourne",
            "@id": "60019578",
            "affilname": "Monash University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60019578",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Melbourne",
            "@id": "60008014",
            "affilname": "The Alfred",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008014",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Barcelona",
            "@id": "60001576",
            "affilname": "Universitat de Barcelona",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60001576",
            "affiliation-country": "Spain"
        }
    ],
    "funding": [
        "Balnaves Foundation",
        "Bristol-Myers Squibb",
        "Novartis",
        "Gilead Sciences",
        "National Health and Medical Research Council"
    ]
}